Rpo LLC Takes $78,000 Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT)

Rpo LLC purchased a new stake in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPTFree Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 16,016 shares of the company’s stock, valued at approximately $78,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in ADPT. AXQ Capital LP bought a new stake in Adaptive Biotechnologies in the third quarter valued at about $58,000. QRG Capital Management Inc. bought a new stake in Adaptive Biotechnologies in the fourth quarter valued at about $71,000. China Universal Asset Management Co. Ltd. increased its holdings in shares of Adaptive Biotechnologies by 350.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 16,747 shares of the company’s stock worth $82,000 after acquiring an additional 13,028 shares in the last quarter. Victory Capital Management Inc. increased its holdings in shares of Adaptive Biotechnologies by 22.5% in the fourth quarter. Victory Capital Management Inc. now owns 19,087 shares of the company’s stock worth $94,000 after acquiring an additional 3,509 shares in the last quarter. Finally, Lewis Asset Management LLC bought a new stake in shares of Adaptive Biotechnologies in the fourth quarter worth about $96,000. Institutional investors own 99.17% of the company’s stock.

Insider Buying and Selling at Adaptive Biotechnologies

In other Adaptive Biotechnologies news, CEO Chad M. Robins sold 48,673 shares of Adaptive Biotechnologies stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $3.43, for a total value of $166,948.39. Following the completion of the transaction, the chief executive officer now directly owns 2,576,701 shares of the company’s stock, valued at approximately $8,838,084.43. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CEO Chad M. Robins sold 48,673 shares of the business’s stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $3.43, for a total transaction of $166,948.39. Following the completion of the transaction, the chief executive officer now owns 2,576,701 shares of the company’s stock, valued at approximately $8,838,084.43. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Tycho Peterson sold 15,456 shares of the business’s stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $3.44, for a total value of $53,168.64. Following the transaction, the chief financial officer now directly owns 531,553 shares of the company’s stock, valued at approximately $1,828,542.32. The disclosure for this sale can be found here. Insiders sold 124,307 shares of company stock valued at $428,090 in the last three months. Corporate insiders own 6.20% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the company. JPMorgan Chase & Co. lowered their price target on Adaptive Biotechnologies from $11.00 to $8.00 and set an “overweight” rating for the company in a report on Thursday, February 15th. BTIG Research lowered their price target on Adaptive Biotechnologies from $6.00 to $5.00 and set a “buy” rating for the company in a report on Thursday, April 4th. Finally, The Goldman Sachs Group decreased their price objective on Adaptive Biotechnologies from $11.00 to $5.00 and set a “neutral” rating for the company in a report on Friday, February 16th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, Adaptive Biotechnologies presently has a consensus rating of “Moderate Buy” and a consensus price target of $6.80.

Get Our Latest Stock Analysis on Adaptive Biotechnologies

Adaptive Biotechnologies Price Performance

ADPT stock traded down $0.12 during mid-day trading on Wednesday, reaching $3.53. The company had a trading volume of 164,217 shares, compared to its average volume of 1,558,563. Adaptive Biotechnologies Co. has a 52 week low of $2.28 and a 52 week high of $9.08. The stock has a 50 day simple moving average of $3.06 and a two-hundred day simple moving average of $3.81. The company has a market capitalization of $520.21 million, a price-to-earnings ratio of -2.36 and a beta of 1.27.

Adaptive Biotechnologies (NASDAQ:ADPTGet Free Report) last issued its earnings results on Tuesday, May 7th. The company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.02. The company had revenue of $41.87 million during the quarter, compared to the consensus estimate of $38.78 million. Adaptive Biotechnologies had a negative return on equity of 56.58% and a negative net margin of 123.24%. The firm’s revenue for the quarter was up 11.2% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.40) EPS. On average, equities analysts predict that Adaptive Biotechnologies Co. will post -1.3 EPS for the current year.

Adaptive Biotechnologies Profile

(Free Report)

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.

Recommended Stories

Want to see what other hedge funds are holding ADPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Adaptive Biotechnologies Co. (NASDAQ:ADPTFree Report).

Institutional Ownership by Quarter for Adaptive Biotechnologies (NASDAQ:ADPT)

Receive News & Ratings for Adaptive Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptive Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.